SubHero Banner
Text

Xeomin® (incobotulinumtoxinA) – New indication

July 3, 2018 - Merz North America announced the FDA approval of Xeomin (incobotulinumtoxinA), for the treatment of chronic sialorrhea in adult patients.

Download PDF